Why the study?
Perioperative fluid management during pediatric brain tumor resection presents significant challenges and risks, including hemorrhagic shock, pulmonary edema, and congestive heart failure.
Does bioreactance-guided fluid therapy improve outcomes and prevent complications in infants undergoing giant brain tumor excision?
Does bioreactance-guided fluid therapy improve outcomes and prevent complications in infants undergoing giant brain tumor excision?
Bioreactance-guided fluid therapy may be safely used to manage complex intraoperative fluid requirements and prevent complications in infants undergoing major neurosurgery.
Case illustrates fluid management risks in neonatal giant tumor resection; leaves open optimal protocols for prospective validation.
Pediatric patients are more likely to suffer from brain tumors. Surgical resection is often the optimal treatment. Perioperative management of pediatric brain tumor resection brings great challenges to anesthesiologists, especially for fluid therapy. In this case, the infant-patient was only 69-day-old, weighed 6 kg，but she was facing a gaint brain tumor (7.9 cm × 8.1 cm × 6.7 cm) excision. The infant was at great risks such as hemorrhagic shock, cerebral edema, pulmonary edema, congestive heart failure, coagulation dysfunction, etc. However, we tried to use the parameters obtained by bioreactance-based NICOM ® device (Cheetah Medical) to guide the infant’s intraoperative fluid therapy, and successfully avoided these complications and achieved a good prognosis.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: